We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Lab-Based COVID-19 PCR Tests Fail to Distinguish New ‘Stealth’ Version of Omicron from Other Variants

By LabMedica International staff writers
Posted on 09 Dec 2021
Print article
Illustration
Illustration

Omicron, the new SARS-CoV-2 variant, lacks a specific feature that allows PCR tests to distinguish probable cases among COVID-19 positive individuals, according to a report by The Guardian.

Scientists claim to have identified a “stealth” version of Omicron that cannot be distinguished from other SARS-CoV-2 variants using PCR tests utilized by public health officials to gain an understanding of its spread globally. The first Omicron (B.1.1.529) case was reported to the World Health Organization (WHO) on November 24. Just two days later, the WHO designated the variant a Variant of Concern (VOC), based on its unusually large number of mutations and early evidence of its spread. Despite a series of rapidly implemented travel bans, it has now been reported in Africa, many European countries, and a few in Asian countries.

The newly-discovered variant of Omicron shares several mutations with the standard Omicron, but lacks a specific genetic change that allows probable cases to be flagged by lab-based PCR tests. Most PCR machines look for three genes in the virus, although Omicron (and the prior variant Alpha) test positive on only two of these machines due to a genetic change called a deletion in the “S” or spike gene in both Omicron and Alpha. As a result of this glitch, PCR tests that display the so-called “S gene target failure” are highly suggestive of Omicron infections. The commonly used tests can still detect the stealth variant of Omicron as coronavirus, and genomic testing can identify it as the Omicron variant, although routine PCR tests that deliver quicker results can fail to flag probable cases.

Following the discovery of the new form of the Omicron variant, researchers have now split the B.1.1.529 lineage into standard Omicron, known as BA.1, and the newer variant, known as BA.2. Some researchers have now termed the new variant as “stealth Omicron” due to its lack of deletion that allows it to be spotted by PCR tests. Despite falling under Omicron, the stealth variant is so genetically distinct that it could qualify as a new VOC if it spreads rapidly. Researchers are worried over the arrival of two variants, BA.1 and BA.2, in quick succession with shared mutations that could indicate public health surveillance “is missing a big piece of the puzzle”.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Chagas Disease Test
LIAISON Chagas

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.